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Progressive glomerulonephritis and attendant end-stage
renal disease (ESRD) result from antineutrophil cytoplasmic
antibody (ANCA)-associated vasculitis. The optimum time of
kidney transplantation in patients with ESRD due to
ANCA-associated vasculitis (AAV) and the risk of renal or
nonrenal recurrence of vasculitis after transplantation are
unknown. To answer some of these questions, we followed
35 transplant recipients with diagnoses of microscopic
polyangiitis (20 patients) and Wegener’s granulomatosis
(15 patients). The median time from diagnosis to
transplantation was 25 months with all patients being in
clinical remission. Fifteen patients were ANCA-positive at
time of the transplant with 13 preemptive transplants. The
most common immunosuppressive strategy included
antibody induction, corticosteroid, mycophenolate mofetil,
and tacrolimus with acute rejection occurring in eight cases.
Overall and death-censored graft survivals were 94 and
100%, respectively, 5 years post-transplantation. Nonrenal
relapse occurred in three patients with a satisfactory
response to treatment. No clear risk factor to relapse
emerged and no detrimental effect to renal function was
found. We conclude that transplantation should be
considered as the treatment of choice for ESRD due to AAV.
Potent antirejection regimes are well tolerated in these
patients, are associated with a low risk of recurrence and an
absence of AAV-related graft dysfunction.
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Pauci-immune glomerulonephritis is the most common
cause of rapidly progressive glomerulonephritis.1
The majority of cases are associated with circulating
antineutrophil cytoplasmic antibodies (ANCAs) and with
renal histology characterized by glomerular necrosis
and crescent formation.2 Standard treatment for ANCA-
associated vasculitis (AAV) consists of the combined use
of corticosteroid and cyclophosphamide.3 This form of
therapy is effective in controlling the disease in approxi-
mately 90% of patients but is also associated with significant
adverse effects and may not prevent permanent target-
organ damage, particularly if started late in the disease
course. Overall prognosis continues to be dependent on rapid
diagnosis and prompt institution of therapy. The two major
subtypes of AAV are Wegener’s Granulomatosis (WG) and
microscopic polyangiitis (MPA) both of which may
cause end-stage renal disease (ESRD). Over 20% of patients
with AAV will develop ESRD during their lifetime, and
epidemiological studies suggest that this proportion is
increasing.4–7
Kidney transplantation (KTx) improves both the life
expectancy and the quality of life in patients with ESRD.
Consequently, it is the preferred treatment option for patients
needing renal replacement therapy.8,9 KTx has been success-
fully performed in patients with ESRD secondary to
AAV.7,10–13 However, relapses of AAV have been reported in
as many as 50% of cases following KTx and may adversely
affect allograft outcome.4,5,14–21 A pooled analysis of 127
patients indicated that AAV recurred in 17.3% of patients
after KTx.22 The majority of these patients (65%) received
cyclosporin A (CsA) and specific data about immunosup-
pression were not available in the rest. In contrast, a single
center analysis of 33 patients with AAV who underwent KTx
between 1968 and 2000 identified only a single extrarenal
relapse during an average follow-up of 62757 months.23
These discrepancies and the paucity of information regarding
transplant outcomes for AAV in the modern era of
immunosuppression led us to review the outcome of patients
with AAV who had received KTx at our center during the past
decade.
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RESULTS
Patient characteristics
Characteristics of the 35 KTx recipients with native kidney
failure due to AAV are summarized in Table 1. The primary
form of AAV was WG in 15 patients and MPA in 20. The
mean age at transplantation was 44720 years. Eighteen were
males and 17 females. Living donor source was predominant
(88%) and over one-third (37%) of the transplants were
carried out preemptively before the need for dialysis. The
median time interval between last documented clinical
activity of AAV and KTx was 6 months (range 4–120
months). At the time of transplantation, ANCA testing by
immunofluorescence was carried out in 34 of 35 patients and
was positive in 15 of 34 (43%). For these 15, the
pretransplant levels of myeloperoxidase (MPO) and PR3-
ANCA were 47.5759.5 (n¼ 12) and 52.0764 EU/ml (n¼ 3),
respectively.
The majority (74%) of patients were receiving some form
of maintenance immunosuppression for AAV immediately
before KTx (see Table 1 for details).
Post-transplant immunosuppression and clinical outcomes
Post-KTx immunosuppression and major clinical outcomes
are summarized in Table 2. At the time of transplantation all
patients received intravenous methylprednisolone (500, 250,
125, and 90 mg on days 1–4 post-KTx, respectively). Twenty-
two patients (63%) received intravenous induction therapy
with rabbit antithymocyte globulin (1.5 mg/kg/day for a total
of 4–6 doses), five (14%) received basiliximab (40 mg on days
0 and 4), one (3%) received anti-CD52 monoclonal antibody,
and seven (20%) received no induction antibody. Oral
immunosuppression consisted of prednisone 60 mg/day
tapered to 5–10 mg/day by 3 months and various combina-
tions of the following agents: mycophenolate mofetil (MMF)
750–1000 mg twice daily; azathioprine (AZA) 100 mg twice
daily; tacrolimus (TAC) adjusted to a target trough blood
level of 10–15 ng/ml for 3 months and 6–10 ng/ml thereafter;
sirolimus adjusted to a target trough blood level of 15–20 mg/
ml for 3 months and 8–15 ng/ml thereafter; and microemul-
sion CsA adjusted to a target trough blood level of
200–250 ng/ml for 3 months and 150–200 ng/ml thereafter.
The most common oral immunosuppressive regimens were
TAC/MMF and cyclosporine (CsA)/MMF that were em-
ployed in 22 (63%) and seven (20%) cases, respectively.
Clinical outcomes were followed until patient death, graft
loss with return to dialysis or most recent documentation of
graft status. The mean post-KTx follow-up was 4.472.5
years. Biopsy-proven acute rejection occurred in a total of six
recipients (23%) and polyomavirus (BK)-associated nephro-
pathy occurred in three (6%). Glomerular filtration rate was
measured by iothalamate clearance in 30 patients at routine
follow-up 1 year post-KTx. Mean glomerular filtration rate
for these recipients was 57719 ml/min/1.73 m2 indicating
generally excellent graft function at this time point.
Kaplan–Meier plots for overall graft survival and death-
censored graft survival are shown in Figure 1. As shown, a
total of four patient deaths occurred between 2 and 6 years
Table 1 | Baseline characteristics of KTx recipients with native
kidney failure due to AAV
Patient number 35
Form of AAV (WG : PA) 15:20
History of prior KTx, n (%) 6 (17%)
ANCA-positive at time of KTx, n (%) 15/34 (43%)
Age at transplant (Mean7s.d., years) 44720
Gender (M:F) 18:17
Donor Source, n (%)
LRD 26 (74%)
LURD 5 (14%)
DD 4 (12%)
Preemptive KTx, n (%) 13 (37%)
Time on dialysis (median (range), months) 6 (0–60)
Time between last AAV activity and KTx
(Median (range), months)
25 (4–120)
Immunosuppressive therapy at the time of KTx, n (%)
None 9 (26%)
Prednisone alone 16 (45%)
Prednisone plus MMF 7 (20%)
MMF alone 1 (3%)
AZA alone 1 (3%)
AZA plus prednisone 1 (3%)
ANCA, antineutrophil cytoplasmic antibody; AAV, ANCA-associated vasculitis; AZA,
azathioprine; DD, deceased donor; LRD, living related donor; LURD, living unrelated
donor; MMF, mycophenolate mofetil; MPA, microscopic polyangiitis; WG, Wegener’s
granulomatosis.
Table 2 | Kidney transplant-related immunosuppression and
post-transplant outcomes
Induction immunosuppression, n (%)
None 7 (20%)
Anti-CD25 monoclonal antibody 5 (14%)
Antithymocyte globulin 22 (63%)
Anti-CD52 (alemtuzumab) 1 (3%)
Primary oral immunosuppressant, n (%)
TAC/MMF 22 (63%)
CsA/MMF 7 (20%)
CsA/SRL 2 (5%)
SRL/MMF 2 (5%)
TAC/SRL 1 (3%)
TAC/AZA 1 (3%)
Follow-up (mean7s.d., years) 4.472.5
Acute rejection, n (%) 6 (23%)
Polyomavirus (BK)-associated nephropathy 3 (6%)
GFR at 1 year post-KTx (mean7s.d., ml/min/1.74m2) 57719 (n=30)
Clinical relapse (nonrenal) of AAV, n (%)
Total group 3/35 (8.6%)
WG group 2/15 (13%)
MPA group 1/20 (5%)
ANCA-positive at time of KTx 2/15 (13%)
ANCA-negative at time of KTx 1/19 (5%)
CsA-based regimen 2/9 (22%)
TAC-based Regimen 1/24 (4%)
AZA, azathioprine; CsA, cyclosporine; GFR, glomerular filtration rate; MMF, myco-
phenolate mofetil; MPA, microscopic polyangiitis; SRL, sirolimus; TAC, tacrolimus;
WG, Wegener’s granulomatosis.
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following KTx and an additional two grafts were lost
between 6 and 8 years post-KTx. Deaths were due to cancer
(n¼ 2), intracranial hemorrhage (n¼ 1), and unexplained
sudden death (n¼ 1). Other graft losses were due to acute
rejection due to noncompliance (n¼ 1) and chronic allograft
nephropathy (n¼ 1). Overall graft survival at 5 years was
94% with death-censored graft survival of 100% at this time
point.
Post-KTx relapses of AAV
Relapse of AAV was documented in three of 35 (8.6%)
patients at 20, 24, and 68 months post-KTx. Two relapses
occurred in patients with WG and one in a patient with MPA
giving recurrence rates of 13 and 5% for the two forms of
AAV (P¼NS). One relapse occurred following withdrawal of
CsA for gingival hyperplasia and a second occurred in a
patient receiving maintenance doses of CsA and AZA. Only
one of 24 (4%) KTx recipients receiving a TAC-based
regimen had AAV relapse. Of those tested for ANCA at the
time of KTx, two of 15 ANCA-positive cases had subsequent
AAV (13%) compared with one of 19 ANCA-negative cases
(5%) (P¼NS).
In all three cases, the relapse was nonrenal in nature with
normal urinalysis, stable serum creatinine concentration,
and/or normal renal allograft biopsy at the time of clinical
relapse. Symptomatic presentation involved upper respira-
tory tract alone (n¼ 1); upper respiratory tract and multiple
joints (n¼ 1); and upper respiratory tract, joints, and skin
(n¼ 1). All three relapses were associated with elevated
ANCA (anti-MPO in one case and anti-PR3 in two cases)
and with a tissue biopsy diagnostic of vasculitis. Treatment
consisted of increased prednisone and conversion from AZA
into MMF (n¼ 1); increased prednisone and initiation of
TAC (n¼ 1); and combined therapy with methylprednisolone
and rituximab (n¼ 1). Two patients required retreatment for
persistent or recurrent symptoms but all have achieved
prolonged clinical and laboratory remission with stable renal
allograft function at most recent follow-up (Table 2).
Post-transplant ANCA assays
A total of 18 patients had follow-up ANCA testing carried out
1 or more years post-KTx. Of these, 12 had been ANCA-
negative immediately pre-KTx and nine of 12 (75%)
remained ANCA-negative post-KTx. Of the three that
converted to ANCA-positive post-KTx, one became positive
(anti-PR3 9.1 EU/ml) at 1 year, but negative (anti-PR3
o5 EU/ml) at 2 years; one became positive (anti-MPO
15.2 EU/ml) at 1 year, but negative (anti-MPOo5 EU/ml) at
2 and 3 years; and one became ANCA-positive at 8 years.
Only the latter case suffered a clinical relapse of AAV. Of the
six patients who were ANCA-positive immediately pre-KTx
and had post-KTx ANCA testing performed, only one
became ANCA-negative at 1 year and remained relapse-free.
Four remained ANCA-positive, but had reduced ANCA levels
compared with pre-KTx. One of these subsequently relapsed
in association with an increased ANCA level (anti-MPO 97.3
to 4320 EU/ml). In total, eight of 18 (44%) patients tested
had at least one positive post-KTx ANCA test result, three of
whom (38%) suffered a relapse.
DISCUSSION
We studied 35 patients with AAV who underwent a kidney
transplant at Mayo Clinic during the 10-year time period
between 1996 and 2005. This is the largest reported cohort of
patients with AAV to undergo transplantation in recent years
at one center, allowing the assessment of transplant outcomes
and relapse rates of AAV in the era of modern immunosup-
pression. In our series, relapses of AAV were relatively rare
(9%), occurred beyond the first post-transplant year and did
not directly or indirectly affect allograft function.
There are a number of published reports indicating that
renal transplantation is an excellent option for the treatment
of patients with AAV who reach ESRD. Data from the
Collaborative Transplant Study show that patients with AAV
who received a deceased donor KTx had a 10-year graft
survival rate of 80%.24 Similarly, in a case series of 22 AAV
patients who underwent transplantation, Allen et al.4
reported post-KTx patient survival of 100 and 85% at 1
and 5 years, respectively, whereas graft survival for the same
time periods were 86 and 69%, respectively. Our data for
more recently transplanted patients provide similar reassur-
ance of excellent overall patient and graft outcomes for KTx
recipients with a history of AAV.
In contrast, reports of relapse rates and severity of AAV
following KTx have varied widely.4,14–20,22,23,25 Nachman
et al.,22 combining their experience in 26 cases from the
University of North Carolina, USA and the University of
Lund, Sweden with 101 previously reported cases, derived a
post-KTx relapse rate of 17.3%. Renal involvement occurred
in 12 of 22 relapse cases (55%) and resulted in graft loss or
declining function in four of 12. Extrarenal relapse alone
occurred in 10 cases. Among the 85 patients treated with
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Figure 1 | Kaplan–Meier curves are shown for overall kidney
transplant survival (Graft Survival) and death-censored kidney
transplant survival among 35 recipients with ESRD due to AAV.
wPatient death with functioning kidney transplant.
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CsA, a relapse was documented in 17 patients, corresponding
to a relapse rate of 20%. No statistical difference was found
between relapse rates in patients diagnosed with WG versus
MPA, between patients treated with CsA versus those not
receiving CsA, or between patients who were ANCA-positive
at the time of transplantation versus those who were ANCA-
negative. In a smaller study, Elmedhem et al.25 evaluated the
outcome of nine patients with AAV transplanted between
1987 and 2000 and managed with prednisolone, AZA and
CsA. Two patients (22%) with WG had minor relapses
affecting the upper respiratory tract that went into remission
after prednisolone, cyclophosphamide, and co-trimoxazole
treatment. Although no allograft biopsy was performed,
serum creatinine levels remained unchanged during the
episodes and no allograft was lost due to a relapse of AAV.
More recently, Deegens et al.,23 studied the outcome of KTx
in 33 patients with AAV transplanted between 1968 and 2000
under varying immunosuppressive regimens. ANCA testing
was carried out in 18 patients around the time of
transplantation, and positive ANCA by immunofluorescence
was found in eight patients (8/18; 44%). Only one patient
(3%) with WG developed an extrarenal relapse, with none of
the patients developing a renal relapse. Overall, the results we
report here are in keeping with low post-KTx relapse rate
among patients transplanted during a period characterized by
predominant use of induction therapy and potent three-drug
oral immunosuppression. Furthermore, AAV relapses among
this cohort were exclusively nonrenal and responsive to
therapy. If we consider that in two of the three cases of a
relapse, it occurred in patients who received no induction
therapy and had been treated with AZA, in combination with
either prednisone, or prednisone and CsA, then relapses in
the group treated with antithymocyte globulin induction,
combined with TAC/MMF, and prednisone were even rarer
(4%).
ANCA screening was not carried out routinely post-KTx
in our patients. This and the small number of relapses
preclude a formal analysis of ANCA as a predictor of disease
or renal relapse. However, our data indicate that ANCA
positivity is not uncommon following KTx for AAV, and it
does not seem to be useful as a predictor of disease relapse.
The production of specific antibodies in AAV suggests an
antigen-driven pathogenic mechanism which may depend
upon help from T cells.26,27 Antithymocyte globulin has been
used in patients with severe refractory WG,28 and antithy-
mocyte globulin is commonly used for induction of
immunosuppression in transplant patients. It is possible that
its use could have a beneficial long-term impact in the disease
process of AAV.
The potential protective role for MMF in this patient
cohort merits specific discussion. The superiority of MMF
over AZA in preventing acute rejection in KTx recipients has
been well shown in multicenter randomized studies.29,30
Several recent studies have addressed the use of MMF for the
treatment of AAV with varying results. Stegeman et al.31 have
used MMF for induction of remission in patients with active
WG who were intolerant of cyclophosphamide. Eleven
achieved complete remission, two had partial remissions,
and three subsequently relapsed. Nowack et al.32 used MMF
together with low dose prednisone as maintenance therapy
for 15 months in 11 patients with AAV. Only one patient
relapsed in the fourteenth month of maintenance therapy.
Similarly, Langford et al.33 examined the safety of single
therapy with MMF for remission maintenance in 14 patients
with WG who had been treated with oral cyclophosphamide
and steroids to induce remission. Remission occurred in all
patients after a median of 3 months, but six (43%)
subsequently relapsed. More recently, Joy et al.34 reported a
study of MMF used in combination with prednisone in 12
patients with relapsing or cyclophosphamide-resistant ANCA
vasculitis. Three experienced an early and sustained decrease
in disease activity, three experienced an early improvement
followed by one relapse and five had delayed or poor
response to treatment. Although we postulate that the
widespread incorporation of antibody induction, TAC and
MMF into immunosuppressive regimens for KTx recipients
during the past decade has served to further reduce the risk of
AAV relapse from 15–20% to 5–10% and to virtually eliminate
renal allograft involvement, no definitive conclusion can be
derived from the current or previous studies regarding the
role of specific immunosuppressive regimens in modulating
disease recurrence.
The question of the optimal timing for KTx in AAV
patients remains open to debate. Although there is general
consensus that AAV should be in clinical remission at the
time of transplantation,22 a minority of WG patients have
persistent smoldering disease, especially in the upper
respiratory tract. Although successful KTx has been described
in such patients, none of the cases reported here were in this
category and, in common with published opinion,19 our
ongoing practice is to postpone transplantation until
complete clinical remission is achieved. The necessity for
negative ANCA testing before proceeding with KTx is less
well agreed upon, although most analyses conclude that the
presence of ANCA at transplantation is not associated with
an increased rate of relapse.35 In the current study, although
there was a trend toward higher relapse rate among patients
who had a positive ANCA test before KTx (13 versus 5%), the
difference was not statistically significant and relapses among
both groups were infrequent and clinically manageable.
This study represents one of the larger single-center
experiences with KTx for AAV and is specifically relevant to
current practice trends in transplantation. Clearly, some
important limitations should be borne in mind including the
study’s retrospective nature and relatively small case number
which preclude more robust statistical analysis of risk factors
for relapse. Extrapolation of these results to centers in which
differing patient demographics and disease severity exist
must also be carried out with caution. Nonetheless, when
taken together with the results of existing reports, our
experience with this patient cohort strongly supports the
conclusion that KTx is the treatment of choice for patients
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with impending ESRD due to AAV who are in an established
clinical remission from systemic manifestations of the disease
regardless of ANCA status. Our results also provide
reassurance that potent post-KTx immunosuppressive regi-
mens are well tolerated in those previously treated for AAV
and are associated with low risk of recurrence and virtual
absence of AAV-related graft dysfunction.
MATERIALS AND METHODS
Study population
All KTx performed at Mayo Clinic between January 1996 and
December 2005 were reviewed for cause of native kidney failure. Of
2452 KTx performed during this period 35 (1.4%) involved
recipients in whom AAV was determined to be the primary cause
for native kidney failure. For the purposes of this study, the diagnosis
of AAV required clear documentation of each of the following: (a) a
compatible clinical syndrome, (b) biopsy-proven vasculitis (e.g.
necrotizing pauci-immune crescentic GN in the case of a kidney
biopsy or presence of vasculitis and granuloma in the case of a lung
or other tissue biopsy), and (c) positive blood assay for perinuclear
(p) or cytoplasmic (c) ANCA. Patients were classified as WG or MPA
according to the criteria of the American College of Rheumatology
and the Chapel Hill consensus.2,36 Documentation of anti-proteinase
3 (PR3) or anti-MPO antibodies was not a prerequisite for inclusion
because antigen-specific ANCA testing was not a routinely
performed at our institution until January 2000. However, if a
biopsy was performed elsewhere but slides could not be reviewed at
our institution, a positive test result for PR3- or MPO-ANCA was
required in addition to documentation of clinical and biopsy
findings of vasculitis in the medical record.
Data acquisition and analysis
Clinical, histological, and laboratory data were abstracted from the
medical records of all cases meeting study entry criteria. Data
regarding demographics, prior transplants, donor source, time on
dialysis, and ANCA status before KTx, type of immunosuppression,
occurrence of acute rejection, iothalamate glomerular filtration rate
at 1 year post-KTx, graft loss, status at most recent follow-up and
evidence of AAV relapse were recorded. Criteria for determination of
AAV relapse were generated before data acquisition and consisted of
one or more of the following: (a) an episode of increased serum
creatinine concentration accompanied by nephritic urinary sediment
(425% dysmorphic red cells and/or red cell casts) in the absence of
other cause for renal allograft dysfunction, (b) an allograft biopsy
reported as showing active necrotizing, pauci-immune, crescentic
glomerulonephritis, (c) an episode of hemoptysis, pulmonary
hemorrhage, or new or expanding nodules without evidence of
infection, (d) occurrence of active vasculitis of respiratory or
gastrointestinal tracts confirmed by endoscopic or open biopsy, (e)
necrotizing vasculitis identified by any other tissue biopsy, (f) an
episode of iritis or uveitis without other documented cause, or (g) a
new diagnosis of mononeuritis multiplex.6,37 The effects of AAV
subtype, CsA-based versus TAC-based immunosuppression and
ANCA status at the time of transplantation on frequency of AVV
relapse were examined. Overall and death-censored graft survival
rates were examined by Kaplan–Meier survival curves.
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